GSK strikes up to $750 million deal for cancer-targeting drug

GSK

15/09/2026 07:10

Sept 15 (Reuters) - GSK GSK.L said on Tuesday it had agreed to a deal worth up to $750 million to buy a trispecific T cell-engager, a drug designed to help T-cells target cancer, from private biotechnology firm Chimagen Biosciences.

 (Reporting by Shashwat Awasthi in Bengaluru; Editing by Sonia Cheema)
 ((Shashwat.Awasthi@tr.com))